|
|
|
|
| LEADER |
00000cam a22000007a 4500 |
| 001 |
SCIDIR_on1353580863 |
| 003 |
OCoLC |
| 005 |
20231120010717.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
221207s2022 xx o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d EBLCP
|d UKAHL
|d AUD
|d OCLCF
|d OCLCO
|
| 019 |
|
|
|a 1354206713
|a 1355690162
|
| 020 |
|
|
|a 9780443132483
|q (electronic bk.)
|
| 020 |
|
|
|a 0443132488
|q (electronic bk.)
|
| 020 |
|
|
|z 9780443132476
|
| 020 |
|
|
|z 044313247X
|
| 035 |
|
|
|a (OCoLC)1353580863
|z (OCoLC)1354206713
|z (OCoLC)1355690162
|
| 050 |
|
4 |
|a RC271.C5
|
| 082 |
0 |
4 |
|a 616.9940636
|2 23
|
| 100 |
1 |
|
|a Xie, Tian.
|
| 245 |
1 |
0 |
|a Elemene antitumor drugs :
|b molecular compatibility theory and its applications in new drug development and clinical practice /
|c Tian Xie.
|
| 260 |
|
|
|a [S.l.] :
|b Elsevier,
|c 2022.
|
| 300 |
|
|
|a 1 online resource
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Intro -- Title page -- Table of Contents -- Copyright -- Forward I -- Forward II -- Part 1. Development of Elemene Antitumor Drug Based on Molecular Compatibility -- Chapter 1. Molecular Compatibility Theory and Its Applications in Tumor Treatment -- 1.1. Developmental history of Chinese medicine compatibility -- 1.2. Theoretical basis and characteristics of molecular compatibility theory -- 1.3. Applications of molecular compatibility -- 1.4. Significance of developing the molecular compatibility theory
|
| 505 |
8 |
|
|a 1.5. Development of research methods of modern Chinese medicines by molecular compatibility theory -- 1.6. Innovative strategies for clinical treatment of systematic and complicated diseases provided by molecular compatibility theory -- 1.7. Conclusions -- Chapter 2. Research and Development of The Antitumor Drug Elemene Liposome -- 2.1. Research and development history of elemene liposome -- 2.2. Market application of elemene liposome -- 2.3. Conclusions -- Part 2. Drug Sources of Elemene -- Chapter 3. Traditional Extraction and Separation, Manufacturing Process, and Quality Standards of Elemene
|
| 505 |
8 |
|
|a 5.2. Apoptosis -- 5.3. Nonapoptotic cell death -- 5.4. Antimetastasis -- 5.5. Immune system -- 5.6. Cell cycle arrest -- 5.7. Regulation of differentiation -- 5.8. Conclusions -- Chapter 6. Antitumor Mechanisms of Elemene in Specific Cancers -- 6.1. Antitumor mechanisms of elemene in primary liver cancer -- 6.2. Antitumor mechanisms of elemene in lung cancer -- 6.3. Antitumor mechanisms of elemene in gastric cancer -- 6.4. Antitumor mechanisms of elemene in glioma -- 6.5. Antitumor mechanisms of elemene in other cancers -- 6.6. Conclusions
|
| 505 |
8 |
|
|a Part 4. Clinical Research on Molecular Compatibility of Elemene -- Chapter 7. Clinical Applications of Elemene -- 7.1. Introduction -- 7.2. Lung cancer -- 7.3. Gastric cancer -- 7.4. Esophageal cancer -- 7.5. Liver cancer -- 7.6. Colorectal cancer -- 7.7. Pancreatic cancer -- 7.8. Breast cancer -- 7.9. Cervical cancer -- 7.10. Nasopharyngeal carcinoma -- 7.11. Leukemia -- 7.12. Malignant lymphoma -- 7.13. Intracranial tumors -- 7.14. Osseous metastasis of the malignant tumors -- 7.15. Malignant pleural effusion -- 7.16. Cancer-related fatigue -- 7.17. Cancer pain -- 7.18. Bladder cancer
|
| 650 |
|
0 |
|a Tumors
|x Chemotherapy.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
6 |
|a Tumeurs
|0 (CaQQLa)201-0079779
|x Chimioth�erapie.
|0 (CaQQLa)201-0379519
|
| 650 |
|
6 |
|a M�edicaments
|x D�eveloppement.
|0 (CaQQLa)201-0306620
|
| 650 |
|
7 |
|a Drug development
|2 fast
|0 (OCoLC)fst00898670
|
| 650 |
|
7 |
|a Tumors
|x Chemotherapy
|2 fast
|0 (OCoLC)fst01158763
|
| 776 |
0 |
8 |
|c Original
|z 044313247X
|z 9780443132476
|w (OCoLC)1350574068
|
| 776 |
0 |
8 |
|i Print version:
|a Xie, Tian, author.
|t Elemene antitumor drugs
|z 9780443132476
|w (OCoLC)1351695052
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780443132476
|z Texto completo
|
